Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeting RAF: trials and tribulations.

Literature DB >> 21383738

Targeting RAF: trials and tribulations.

Julian Downward.

Abstract

Entities: Gene

Mesh：

Substances：

Year: 2011 PMID： 21383738 DOI： 10.1038/nm0311-286

Source DB: PubMed Journal: Nat Med ISSN： 1078-8956 Impact factor: 53.440

× No keyword cloud information.

8 in total

1. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization.

Authors: Mathew J Garnett; Sareena Rana; Hugh Paterson; David Barford; Richard Marais
Journal: Mol Cell Date: 2005-12-22 Impact factor: 17.970

2. Inhibition of mutated, activated BRAF in metastatic melanoma.

Authors: Keith T Flaherty; Igor Puzanov; Kevin B Kim; Antoni Ribas; Grant A McArthur; Jeffrey A Sosman; Peter J O'Dwyer; Richard J Lee; Joseph F Grippo; Keith Nolop; Paul B Chapman
Journal: N Engl J Med Date: 2010-08-26 Impact factor: 91.245

3. Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K.

Authors: Jessie Villanueva; Adina Vultur; John T Lee; Rajasekharan Somasundaram; Mizuho Fukunaga-Kalabis; Angela K Cipolla; Bradley Wubbenhorst; Xiaowei Xu; Phyllis A Gimotty; Damien Kee; Ademi E Santiago-Walker; Richard Letrero; Kurt D'Andrea; Anitha Pushparajan; James E Hayden; Kimberly Dahlman Brown; Sylvie Laquerre; Grant A McArthur; Jeffrey A Sosman; Katherine L Nathanson; Meenhard Herlyn
Journal: Cancer Cell Date: 2010-12-14 Impact factor: 31.743

4. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation.

Authors: Ramin Nazarian; Hubing Shi; Qi Wang; Xiangju Kong; Richard C Koya; Hane Lee; Zugen Chen; Mi-Kyung Lee; Narsis Attar; Hooman Sazegar; Thinle Chodon; Stanley F Nelson; Grant McArthur; Jeffrey A Sosman; Antoni Ribas; Roger S Lo
Journal: Nature Date: 2010-11-24 Impact factor: 49.962

5. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth.

Authors: Georgia Hatzivassiliou; Kyung Song; Ivana Yen; Barbara J Brandhuber; Daniel J Anderson; Ryan Alvarado; Mary J C Ludlam; David Stokoe; Susan L Gloor; Guy Vigers; Tony Morales; Ignacio Aliagas; Bonnie Liu; Steve Sideris; Klaus P Hoeflich; Bijay S Jaiswal; Somasekar Seshagiri; Hartmut Koeppen; Marcia Belvin; Lori S Friedman; Shiva Malek
Journal: Nature Date: 2010-02-03 Impact factor: 49.962

6. Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

Authors: Sonja J Heidorn; Carla Milagre; Steven Whittaker; Arnaud Nourry; Ion Niculescu-Duvas; Nathalie Dhomen; Jahan Hussain; Jorge S Reis-Filho; Caroline J Springer; Catrin Pritchard; Richard Marais
Journal: Cell Date: 2010-01-22 Impact factor: 41.582

7. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF.

Authors: Poulikos I Poulikakos; Chao Zhang; Gideon Bollag; Kevan M Shokat; Neal Rosen
Journal: Nature Date: 2010-03-18 Impact factor: 49.962

8. COT drives resistance to RAF inhibition through MAP kinase pathway reactivation.

Authors: Cory M Johannessen; Jesse S Boehm; So Young Kim; Sapana R Thomas; Leslie Wardwell; Laura A Johnson; Caroline M Emery; Nicolas Stransky; Alexandria P Cogdill; Jordi Barretina; Giordano Caponigro; Haley Hieronymus; Ryan R Murray; Kourosh Salehi-Ashtiani; David E Hill; Marc Vidal; Jean J Zhao; Xiaoping Yang; Ozan Alkan; Sungjoon Kim; Jennifer L Harris; Christopher J Wilson; Vic E Myer; Peter M Finan; David E Root; Thomas M Roberts; Todd Golub; Keith T Flaherty; Reinhard Dummer; Barbara L Weber; William R Sellers; Robert Schlegel; Jennifer A Wargo; William C Hahn; Levi A Garraway
Journal: Nature Date: 2010-11-24 Impact factor: 49.962

8 in total

15 in total

1. Radiopharmaceutical therapy in the era of precision medicine.

Authors: George Sgouros; David M Goldenberg
Journal: Eur J Cancer Date: 2014-06-19 Impact factor: 9.162

Review 2. [Hairy cell leukemia].

Authors: S Dietrich; M Andrulis; T Zenz
Journal: Internist (Berl) Date: 2015-04 Impact factor: 0.743

3. Randomized phase II trial of sorafenib with temsirolimus or tipifarnib in untreated metastatic melanoma (S0438).

Authors: Kim A Margolin; James Moon; Lawrence E Flaherty; Christopher D Lao; Wallace L Akerley; Megan Othus; Jeffrey A Sosman; John M Kirkwood; Vernon K Sondak
Journal: Clin Cancer Res Date: 2012-01-06 Impact factor: 12.531

4. Distinct requirement for an intact dimer interface in wild-type, V600E and kinase-dead B-Raf signalling.

Authors: Michael Röring; Ricarda Herr; Gina J Fiala; Katharina Heilmann; Sandra Braun; Anja E Eisenhardt; Sebastian Halbach; David Capper; Andreas von Deimling; Wolfgang W Schamel; Darren N Saunders; Tilman Brummer
Journal: EMBO J Date: 2012-04-17 Impact factor: 11.598

5. Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours.

Authors: H Yurugi; F Marini; C Weber; K David; Q Zhao; H Binder; L Désaubry; K Rajalingam
Journal: Oncogene Date: 2017-04-17 Impact factor: 9.867

6. Phosphorylation of BRAF by AMPK impairs BRAF-KSR1 association and cell proliferation.

Authors: Che-Hung Shen; Ping Yuan; Rolando Perez-Lorenzo; Yaqing Zhang; Sze Xian Lee; Yang Ou; John M Asara; Lewis C Cantley; Bin Zheng
Journal: Mol Cell Date: 2013-10-03 Impact factor: 17.970

7. MEK-1 activates C-Raf through a Ras-independent mechanism.

Authors: Deborah T Leicht; Vitaly Balan; Jun Zhu; Alexander Kaplun; Agnieszka Bronisz; Ajay Rana; Guri Tzivion
Journal: Biochim Biophys Acta Date: 2013-01-27

Review 8. Dosimetry for radiopharmaceutical therapy.

Authors: George Sgouros; Robert F Hobbs
Journal: Semin Nucl Med Date: 2014-05 Impact factor: 4.446

Review 9. Attacking a nexus of the oncogenic circuitry by reversing aberrant eIF4F-mediated translation.

Authors: Peter B Bitterman; Vitaly A Polunovsky
Journal: Mol Cancer Ther Date: 2012-05 Impact factor: 6.261

10. Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

Authors: Leisl M Packer; Sareena Rana; Robert Hayward; Thomas O'Hare; Christopher A Eide; Ana Rebocho; Sonja Heidorn; Matthew S Zabriskie; Ion Niculescu-Duvaz; Brian J Druker; Caroline Springer; Richard Marais
Journal: Cancer Cell Date: 2011-12-13 Impact factor: 31.743